RT Journal Article
SR Electronic
T1 Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e008189
DO 10.1136/jitc-2023-008189
VO 12
IS 2
A1 Carbone, David P.
A1 Ciuleanu, Tudor-Eliade
A1 Schenker, Michael
A1 Cobo, Manuel
A1 Bordenave, Stéphanie
A1 Juan-Vidal, Oscar
A1 Menezes, Juliana
A1 Reinmuth, Niels
A1 Richardet, Eduardo
A1 Cheng, Ying
A1 Mizutani, Hideaki
A1 Felip, Enriqueta
A1 Zurawski, Bogdan
A1 Alexandru, Aurelia
A1 Paz-Ares, Luis
A1 Lu, Shun
A1 John, Thomas
A1 Zhang, Xiaoqing
A1 Mahmood, Javed
A1 Hu, Nan
A1 De, Tuli
A1 Santi, Irene
A1 Penrod, John R.
A1 Yuan, Yong
A1 Lee, Adam
A1 Reck, Martin
YR 2024
UL http://jitc.bmj.com/content/12/2/e008189.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.